Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum LP1, also known as LP01, is a specific strain of the probiotic bacterium Lactiplantibacillus plantarum. It is widely studied and utilized as a dietary supplement and nutraceutical for its various health benefits, particularly in supporting gastrointestinal health. The mechanism of action for L. plantarum LP1 involves multiple pathways: it helps maintain a healthy gut microbiota by competitively inhibiting the growth of pathogenic bacteria through the production of antimicrobial substances like lactic acid. It also enhances the gut barrier function, modulates the immune system by interacting with gut-associated lymphoid tissue (GALT), and aids in the fermentation of undigested carbohydrates to produce beneficial short-chain fatty acids (SCFAs). As a probiotic, it is not absorbed into the bloodstream but colonizes the gastrointestinal tract before being excreted. It has been investigated for managing conditions such as irritable bowel syndrome (IBS), constipation, and for mitigating intestinal symptoms following procedures like colonoscopy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus plantarum LP1.